A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy

BACKGROUND: Immunotherapy has emerged as an efficient therapeutic approach for cancer management. However, stimulation of host immune system against cancer cells often fails to achieve promising clinical outcomes mainly owing to the immunosuppressive characteristics of the tumor microenvironment (TM...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahreyni, Amirhossein, Liu, Huitao, Mohamud, Yasir, Xue, Yuan Chao, Fan, Yiyun Michelle, Zhang, Yizhuo Lyanne, Luo, Honglin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210435/
https://www.ncbi.nlm.nih.gov/pubmed/37226233
http://dx.doi.org/10.1186/s12916-023-02901-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210435/
https://www.ncbi.nlm.nih.gov/pubmed/37226233
http://dx.doi.org/10.1186/s12916-023-02901-y

Ejemplares similares